Dartmouth College

Dartmouth Digital Commons
Open Dartmouth: Faculty Open Access Articles

1-5-2016

Non-Alcoholic Fatty Liver Disease Induces Signs of
Alzheimer’s Disease (AD) in Wild-Type Mice and
Accelerates Pathological Signs of AD in an AD
Model
Do-Geun Kim
Cornell University

Antje Krenz
Cornell University

Leon E. Toussaint
Cornell University

Kirk J. Maurer
Dartmouth College

Follow this and additional works at: https://digitalcommons.dartmouth.edu/facoa
Part of the Biochemical Phenomena, Metabolism, and Nutrition Commons, Medical Pathology
Commons, and the Neurology Commons
Recommended Citation
Kim, Do-Geun; Krenz, Antje; Toussaint, Leon E.; and Maurer, Kirk J., "Non-Alcoholic Fatty Liver Disease Induces Signs of
Alzheimer’s Disease (AD) in Wild-Type Mice and Accelerates Pathological Signs of AD in an AD Model" (2016). Open Dartmouth:
Faculty Open Access Articles. 1345.
https://digitalcommons.dartmouth.edu/facoa/1345

This Article is brought to you for free and open access by Dartmouth Digital Commons. It has been accepted for inclusion in Open Dartmouth: Faculty
Open Access Articles by an authorized administrator of Dartmouth Digital Commons. For more information, please contact
dartmouthdigitalcommons@groups.dartmouth.edu.

Kim et al. Journal of Neuroinflammation (2016) 13:1
DOI 10.1186/s12974-015-0467-5

RESEARCH

Open Access

Non-alcoholic fatty liver disease induces
signs of Alzheimer’s disease (AD) in wildtype mice and accelerates pathological
signs of AD in an AD model
Do-Geun Kim1, Antje Krenz1, Leon E. Toussaint1, Kirk J. Maurer2,3,4, Sudie-Ann Robinson1, Angela Yan1,
Luisa Torres1 and Margaret S. Bynoe1*

Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease afflicting about one third of the world’s
population and 30 % of the US population. It is induced by consumption of high-lipid diets and is characterized by liver
inflammation and subsequent liver pathology. Obesity and consumption of a high-fat diet are known to increase the risk
of Alzheimer’s disease (AD). Here, we investigated NAFLD-induced liver inflammation in the pathogenesis of AD.
Methods: WT and APP-Tg mice were fed with a standard diet (SD) or a high-fat diet (HFD) for 2, 5 months, or 1 year to
induce NAFLD. Another set of APP-Tg mice were removed from HFD after 2 months and put back on SD for 3 months.
Results: During acute phase NAFLD, WT and APP-Tg mice developed significant liver inflammation and pathology that
coincided with increased numbers of activated microglial cells in the brain, increased inflammatory cytokine profile, and
increased expression of toll-like receptors. Chronic NAFLD induced advanced pathological signs of AD in both WT and
APP-Tg mice, and also induced neuronal apoptosis. We observed decreased brain expression of low-density lipoprotein
receptor-related protein-1 (LRP-1) which is involved in β-amyloid clearance, in both WT and APP-Tg mice after ongoing
administration of the HFD. LRP-1 expression correlated with advanced signs of AD over the course of chronic NAFLD.
Removal of mice from HFD during acute NAFLD reversed liver pathology, decreased signs of activated microglial cells
and neuro-inflammation, and decreased β-amyloid plaque load.
Conclusions: Our findings indicate that chronic inflammation induced outside the brain is sufficient to induce
neurodegeneration in the absence of genetic predisposition.
Keywords: Alzheimer’s disease, Apolipoprotein E, High-fat diet, Non-alcoholic fatty liver disease, Standard diet

Background
Alzheimer’s disease (AD) is a progressive neurodegenerative disease associated with decline in cognitive function,
impairment in memory, language and visual-spatial coordination, eventually resulting in complete loss of basic
function [1]. Dementia of all forms affects about 5 % of
the population older than 65. There are approximately 5.5
million cases of AD in the USA alone, and this number is
estimated to nearly triple by the year 2040. Moreover, as
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the world population lives longer, AD and dementia are
predicted to constitute a major global health problem in
the aging population of the world [2].
Major pathological hallmarks of AD present as senile
amyloid plaques that are composed of β-amyloid (Aβ)
protein and intracellular neurofibrillary tangles with
characteristic reactive microgliosis and astrogliosis. AD
is characterized by dystrophic neuritis, neuronal loss,
synaptic dysfunction, and cerebral atrophy [1]. AD can
be largely divided into early and late onset forms. Early
onset AD is induced in patients carrying genetic mutations in amyloid precursor protein (APP) and/or presenilin (PS1 or PS2) which induces formation of insoluble
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Aβ. Previous work showed that mice expressing mutated
APP display alterations in exploratory activity as well as elevation of β-amyloid production reminiscent of AD [3, 4].
Late onset AD, also known as sporadic AD, is believed to
be induced by aberrant processing of Aβ resulting in pathological lesions. In general, APP is cleaved by α-secretase
which generates soluble Aβ which has neuroprotective
functions [5]. However, when APP is cleaved by βsecretase-1 (BACE1), it produces Aβ1–42 which is insoluble
and forms amyloid plaques that are pro-apoptotic and
neurodegenerative and are believed to induce cognitive
impairment [6, 7]. While the underlying cause of AD is not
known, advancing age, environmental stressors, and genetic
factors appear to be important precursors [8, 9]. In
addition to Aβ deposits, AD is characterized by
neurofibrillary tangles which are neuronal deposits of
hyperphosphorylated-Tau, also referred to as tauopathies, which are well correlated with cognitive impairment and advanced neurodegeneration [1, 10]. Due to
this association, it is still debated whether the initiating factor of AD is Aβ plaques or tauopathy [11].
In the USA, diets high in fats/lipids, which are commonly known as “fast foods,” are prevalent in a significant portion of the population and are becoming an
important public health issue. High-fat diets are implicated in various metabolic syndromes leading to obesity,
atherosclerosis, insulin resistance, dementia, cognitive
decline, and potentially, AD [12–16]. HFD also induces
a liver pathology called non-alcoholic fatty liver disease
(NAFLD) which is characterized by fatty liver, accumulation of lipids in hepatocytes, infiltration of inflammatory
immune cells in the liver parenchyma, and secretion of
pro-inflammatory cytokines resulting in liver damage
[13, 14, 17, 18]. NAFLD is the fourth leading cause of
liver disease in the Western hemisphere. It afflicts about
30 % of the US population and is the 12th leading cause
of death in the USA among adults 45–54 years [19]. The
increase in NAFLD has been linked to increased prevalence of obesity and metabolic diseases in the USA and
worldwide [7]. NAFLD is associated with marked progressive inflammation, fat deposition, and fibrosis of the
liver [8, 10]. Also, a clear association exists between cardiovascular risk factors or carotid atherosclerosis and
dementia progression leading to AD [20].
Cholesterol is an important building block of the
brain [21], which produces over 20 % of total cholesterol in the body. This high-cholesterol content is
needed for neuronal function, as the brain cannot
access plasma cholesterol due to restrictions posed by
the blood brain barrier [22]. For this reason, neuronal
cells express high levels of cholesterol-uptake receptors
such as low-density lipoprotein receptor (LDLR), lowdensity lipoprotein receptor-related protein 1 (LRP1),
and apoliprotein-E (ApoE). Up to 70 % of the brain’s
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cholesterol make up the myelin sheath of oligodendrocytes and the membrane of astrocytes, with the remainder contributing to neuronal function including the
myelin sheath of neurons that relay synaptic signals.
ApoE and LRP1 are related to cholesterol metabolism
and are important risk factors contributing to the
prevalence of AD [23–25]. The ApoE variant, ApoE4,
increases AD risk and accelerates AD onset (Bu, 2009;
Liu et al., 2013). Multivariate analysis of metabolites in
the blood of AD patients showed that of the ten metabolites that distinguished AD from its age-matched cohorts, six were long-chain cholesteryl esters that were
reduced in AD [26]. Also, several large cohort studies
showed that long-term treatment with statins, which
lowers serum cholesterol levels, could alleviate AD
symptoms, suggesting that alteration in lipid metabolism contributes to AD pathogenesis [27, 28]. LRP1 is
an endocytic receptor highly expressed in the liver, on
neurons, and on vascular smooth muscle and glial cells
in the CNS vasculature and functions in the clearance
of Aβ from the CNS [29]. Aβ clearance is impaired in
neurons from LRP1-deficient mice [30]. Binding of
APP to LRP1 results in increased trafficking and clearance of APP. However, LRP1 is also involved in Aβ production [31]. Hence, its involvement in Aβ synthesis
and clearance makes it a prime target in AD pathogenesis. Deletion of LRP1 exacerbated Aβ deposition and
increased CAA [29]. It is speculated that ApoE may inhibit or facilitate LRP1 endocytosis of Aβ. Since ApoE4
is linked to both sporadic and familial AD and ApoE
functions in the cellular transfer of lipids through LRP1
on the cell surface, it is presumed that LRP1, ApoE, or
both are involved in dysfunction of the lipid transport
mechanism and Aβ clearance.
The increase in obesity and NAFLD prevalence in our
society, both induced by diets high in fats/lipids and their
link to chronic inflammation and metabolic diseases, mirrors increase in AD and AD-like syndromes. We therefore
decided to investigate the impact of NAFLD in AD pathogenesis in an AD transgenic mouse model (APP-Tg) and
in C57BL/6, wild-type (WT) mice.
To elucidate the effect of a diet with increased lipids on
AD pathogenicity, we fed WT and APP-Tg mice with a
high-fat diet (HFD) or standard diet (SD) for 2, 5 months,
or 1 year. HFD induced systemic and CNS inflammation
that accelerated Aβ plaque deposition during acute
NAFLD (2 and 5 months) in APP-Tg mice. In WT mice,
acute NAFLD induced neuro-inflammation but did not
induce Aβ plaques. Removal of HFD after 2 months
decreased Aβ plaque load in APP-Tg mice and reversed
signs of systemic and CNS inflammation in both WT and
APP-Tg mice. WT and APP-Tg mice were kept on HFD
for up to 1 year to determine the impact of chronic
NAFLD in AD induction in WT mice and AD progression
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in APP-Tg mice. We observed advanced signs of AD, including accelerated cerebral amyloid angiopathy (CAA),
increased tauopathy, and increased neuronal loss in APPTg mice. More importantly, long-term HFD treatment
induced plaque formation, CAA, and tauopathy in WT
mice. The advanced signs of AD were associated with a
decrease in CNS expression of LRP1 during chronic
disease. These studies indicate that HFD-induced inflammation plus aging are sufficient to trigger neurodegeneration and accelerate the process of AD even in the absence
of genetic predisposition.

Methods
Mice and diet

The APP-Tg mouse [B6.Cg- Tg (APPswe, PSEN1dE9)85Dbo/J] was generated as previously described [32].
WT mice and their APP-Tg littermates were fed either a
standard diet (SD) (Harlan Teklad TD.7912) or a high-fat
diet (HFD) (1.0 % cholesterol, 0.5 % cholic acid, 18 % triglyceride; Harlan Teklad TD.88051, “Paigen diet”) [14] beginning at the age of 2 months. WT and APP-Tg mice
were fed with SD or HFD for 2, 5 months, or 1 year. Another set of APP-Tg mice were removed from HFD after
2 months and were put back on SD for 3 months. All animal work was done in accordance with PHS guidelines
and was approved by Cornell’s Institutional Animal Care
and Use Committee (Protocol # 2008–0092).
Tissue harvest

Deeply anesthetized mice were weighed and transcardially
perfused with ice-cold phosphate buffered saline (PBS);
then, brain, spleen, and liver were collected for analysis.
After macroscopic photo documentation, all livers were
weighed and used for leukocyte preparation, except two
30-mg tissue sections which were used for histopathology
and RNA preparation. Approximately 30 mg of liver and
one brain hemisphere were flash frozen in Tissue-Tek
O.C.T. (Sakura Finetek) and stored at −80 °C. 10-μm thick
frozen sections were affixed to Superfrost/Plus slides
(Fisher), fixed in acetone, and stored at −80 °C.
Immunohistochemistry

For immunohistochemistry staining, slides were thawed
and treated with 0.03 % H2O2 in PBS to block endogenous peroxidase or fixed and permeabilized in acetone
for immunofluorescence staining, blocked with casein
(Vector Laboratories) in normal goat serum (Zymed),
and then incubated with anti-CD45, phospho-Tau,
ApoE, CD31, LRP-1, 6E10, GFAP, or NeuN primary
antibodies. For immunohistochemistry, slides were then
incubated with biotinylated goat anti-rat Ig (Jackson
ImmunoResearch) and streptavidin-HRP (Zymed) and
developed with an AEC (Red) substrate kit (Zymed),
counter-stained with hematoxylin and mounted with
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Fluoromount-G. For immunofluorescence assay, slides
were instead subjected to AF488, TexRed, or AF647
conjugated secondary antibody and coverslips were
mounted with Vectastain containing DAPI (Vectorlabs).
Standard or frozen histological tissue sections were
formalin-fixed and processed for hematoxylin and eosin
(H&E) or oil red-O staining and hematoxylin counterstaining, respectively, then examined by light microscopy. For the green fluorescent Thioflavine S (ThioS)
staining of plaques, frozen sections were incubated with
1 % ThioS (Sigma-Aldrich) in distilled water for 5 min,
differentiated in 70 % ethanol for 5 min, washed three
times for 5 min each with distilled water and coverslipped with Vectastain containing DAPI (Vectorlabs).
Images were captured using a Zeiss Axio Imager M1
microscope. For further quantification of acquired images,
Zen software (Carl Zeiss) was used to obtain intensities of
signals and counting of positive signals. A detailed explanation on the method of quantification is described in each
figure legend.
TUNEL assay

For TUNEL staining, which was used for detecting cell
death, the reaction mixture supplied by Roche’s In Situ Cell
Death Detection Kit, AP (Cat. No. 11 684 809 910) was
used following the protocol provided by Roche. Briefly, 10μm thin sections of cryogenic brain tissue which were
previously lightly fixed in acetone for 5 min and stored at
−80 °C were thawed and fixed with 4 % paraformaldehyde
for 20 to 30 min. Then, sections were permeabilized using
0.1 % Triton X-100 (Sigma-Aldrich, 9002-93-1) in sodium
citrate (Fisher Scientific, 6132-04-3) with PBS for 2 min.
TUNEL reaction mixture supplied by Roche’s In Situ Cell
Death Detection Kit, AP was added to each section and left
over night at 4 °C. Negative controls received only label
solution and no terminal transferase enzyme, while positive
controls were pretreated with DNase I Recombinant in
50 mM Tris-HCl and 10 mM MgCl2 for 10 min at room
temperature to induce DNA strand breaks. TUNEL reaction mixture was then added to all samples. After washing
with PBS, sections were fixed with 4 % paraformaldehyde
for 10 min and then washed again with PBS. Images were
captured using a Zeiss Axio Imager M1 microscope.
Quantitative PCR

Brain and liver mRNA was extracted with TRIZOL
(Invitrogen) and cDNA was synthesized using HighCapacity cDNA Reverse Transcription Kits (Applied
Biosystems) according to the protocols provided by
the manufacturers. Quantification of expression levels
of ApoE, LRP1, TLR1, TLR2, TLR6, and of proinflammatory cytokines (IL-6, TNF-Α-α, IL-17, and
IL-1β) was performed using specific primers and
KAPA SYBR FAST qPCR Kit (KAPA biosystems) and
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ran on CFX96 thermocycler (Bio-Rad). Relative mRNA
expression levels of genes were analyzed using the 2^dCT
method, normalized with GAPDH as reference gene. The
fold change plotted was relative to the respective SD controls. Specificity of reaction was analyzed using melting
curve analysis. Primer sequences can be viewed in supplemental Table 1.
ELISA assay

Splenocytes were harvested from SD or HFD-fed mice
after 1 year and treated with either PBS or ConA for
48–72 h. Supernatant was collected and used for ELISA
analysis using the eBioscience Ready Set Go Kit. Briefly,
plates were coated overnight at 4 °C with capture antibodies against IL-6, TNF-α, or IL-17 and then washed.
Wells were incubated with standards and samples,
washed, and then subsequently incubated with biotin
conjugated detection antibodies. Plate was washed and
developed with 1× TMB substrate solution (eBioscience)
and the optical density (OD) was read at 450 nm using a
Biotek fluorometer (Biotek). OD values were converted
into absolute concentration using the standard curve.
Detailed quantification method of immunofluorescence
images

For immunofluorescence images, different methods were
used for its quantitative analysis. For plaque quantification,
either sizes or numbers of Thioflavin S+ plaques from
different areas of cortex of animals of different groups were
measured (area size: 6 × 105 μm2/field, ten fields/section,
blindly chosen, five animals/group). Only plaques larger
than 2 × 103 μm2 were measured and smaller plaques were
not considered. For cortical thickness quantification,
lengths of layer I to VI of cortex were measured from
blindly chosen ten different regions of whole cortex from
animals of different groups were measured for analysis
(two animals/group, blindly chosen). For analysis of fragmented vessels, CD31 (vascular marker)-positive cells that
lost normal brain vascular integrity (linear and smooth outlining of vessel) were considered as fragmented vessels, and
the numbers were counted from cortex of animals of different groups (area size: 6 × 105 μm2/field, ten fields/section,
blindly chosen, two animals/group). All analyses (measurement of length, area size) were performed using automatic
calibration function of Zen software (Carl Zeiss).
Western blotting

Brains from WT or APP-Tg mice fed with SD or HFD were
homogenized and lysed with lysis buffer containing protease
inhibitor cocktail. Samples were loaded onto a 10 % SDS
acrylamide gel and separated for 1 h and transferred to a
nitrocellulose paper. The membrane was blocked with 1 %
BSA/TBST and incubated with anti-phospho-Tau antibody
(S396 from abcam, AT8 from Millipore) or anti-Tau
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antibody (Cell signaling) overnight at 4 °C and washed three
times with TBST. For loading control, anti-GAPDH (Cell
signaling) was used. Subsequently, the blot was incubated
with HRP conjugated secondary antibody for an hour at
room temperature and washed three times with TBST. The
blot was developed with Super Signal West Pico ECL solution (Thermo scientific) and exposed to X-ray film. The film
was scanned, and the intensity of each band was analyzed
with Image J software.
Statistical analyses

Data were analyzed by one-way or two-way ANOVA,
followed by Bonferroni’s multiple comparison test or
Student’d t test (two-tailed, unpaired) using GraphPad
Prism 5 software (GraphPad, La Jolla, CA). Plotted data
shown represents Mean ± SEM where significance is
indicated by *p < 0.05, **p < 0.01, ***p < 0.001.

Results
Acute stage NAFLD accelerated β-amyloid plaque
formation in APP-Tg mice but not in WT mice

It is becoming more and more evident that diets high in
fats/lipids can cause metabolic diseases such as NAFLD.
Metabolic diseases are emerging as significant contributors
to dementia and cognitive decline [33, 34]. To investigate
the impact of acute NAFLD in AD pathogenesis, we
induced NAFLD in age- and gender-matched WT and
APP-Tg mice by feeding them a high-fat diet (consisting of
1 % cholesterol and 18 % triglycerides) (Table 1) beginning
at 2 months of age. Mice were fed HFD for 2, 5 months, or
fed HFD for 2 months and put back on standard diet (SD)
for 3 months. Control mice (WT and APP-Tg mice) were
fed SD for either 2 or 5 months. To determine whether
HFD increased β-amyloid (Aβ) plaque burden in APP-Tg
mice, or induced Aβ plaques in WT mice, we analyzed
brain sections of WT and APP-Tg mice on HFD for 2 and
5 months, and of APP-Tg mice that were removed from
HFD after 2 months. We observed a significant increase in
Aβ plaque number in APP-Tg mice fed HFD at 2 and
5 months compared to SD-fed controls as visualized by
Thioflavine S-stained brain sections (Fig. 1a, b). APP-Tg
mice that were removed from HFD after 2 months had
lower plaque burden than mice that were on HFD continuously for 5 months (Fig. 1a, b). Not only was the plaque
burden in APP-Tg mice fed HFD for 5 months greater, the
Table 1 Fat composition of standard diet (SD) and high-fat diet
(HFD)
Fat composition (%)

SD

HFD

Total fat

5.8

15.8

Cholesterol

0

1.0

Cholic acid

0

0

Triglyceride

0

18
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Fig. 1 HFD accelerated β amyloid plaque burden in APP-Tg mice. a Representative images of Thioflavin S (green) and Iba-1 (red) stained cortical brain
sections from age-matched APP-Tg mice. Nucleus was counter-stained with DAPI (blue). Mice were fed with SD (left top panel) or HFD (right top panel) for
2 months. A different set of mice was fed SD for five months (left middle panel) or HFD for 2 months followed by SD for 3 months (right middle panel). A
different set of mice was kept on HFD for 5 months (left bottom panel). Images on the right side are close ups of the plaque clusters seen on the images
on the left. Scale bar = 100 μm. b, c Quantification of Thioflavin S positive plaque number (b) and size (c) in cortical sections of multiple fields (ten fields/
mouse) from five mice/group in one representative experiment out of four independent experiments. * indicates p < 0.05 (One-way ANOVA with
Bonferroni post-test)

plaque sizes were larger in diameter compared to the average plaque size in control mice on SD and were inundated
with activated microglial cells (Fig. 1a, c). We did not observe Aβ plaques in WT mice on HFD either at 2 or
5 months (Additional file 1: Figure S1). We conclude that
HFD accelerated Aβ plaque formation in APP-Tg mice but
did not induce plaques in WT controls. Moreover, removal
of APP-Tg mice from HFD to SD lessened plaque load
compared to mice on HFD for 5 months. This suggests
that if dietary intake is corrected early in disease (prior to
signs of advanced AD), signs of AD can be reversed.

Both WT and APP-Tg mice were susceptible to
HFD-induced NAFLD steatohepatitis and systemic
inflammation

NAFLD induces severe liver inflammation and causes
significant liver damage [18]. To confirm NAFLD induction, we examined the livers of mice and observed that
both WT and APP-Tg mice on HFD exhibited significant
liver abnormality, characterized by severe hepatomegaly,
fat accumulation, and significant increase in liver size
and weight (Fig. 2a, b). Interestingly, when both WT and
APP-Tg mice were removed from HFD after 2 months
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(See figure on previous page.)
Fig. 2 HFD induced acute liver pathology and inflammation in WT and APP-Tg and mice. a Representative images of livers from WT or APP-Tg mice
fed with HFD or SD, with corresponding liver and body weights of their respective age-matched SD-fed controls. Scale bar indicates 5 mm (b). ** and
*** indicate p < 0.01 and p < 0.001, respectively (two-way ANOVA with Bonferroni post-test). c Representative CD45+ staining of liver sections from WT
or APP-Tg mice fed with SD or HFD for 2 months. d Representative oil O-red staining on frozen tissue sections of livers from WT or APP-Tg
mice fed with SD or HFD for 2 months. e Relative positive pixel count of oil O-red staining quantified using Zen software (Carl Zeiss). * and
*** indicate p < 0.05 and p < 0.001, respectively (two-way ANOVA with Bonferroni post-test). f Quantitative analysis of total leukocyte numbers (CD45
+
) isolated from the livers of 2-month SD or HFD-fed WT and APP-Tg mice by flow cytometry. ** indicates p < 0.01 (two-way ANOVA with Bonferroni
post-test, n = 3/group). g TNF-α, IL-6, and IL-17 mRNA expression in livers of WT and APP-Tg mice fed with SD or HFD for 2 months. ** indicates p <
0.01 (two-way ANOVA with Bonferroni post-test, n = 3/group, representative experiment of four independent experiments)

and put back on normal chow for 3 months, the fatty
liver resolved and the size of their liver was similar to
control mice that were continuously on SD (Fig. 2a, b).
Notably, HFD consumption did not lead to abnormal
body weight gain in WT mice. However, in APP-Tg
mice, we observed statistically significant higher body
weight in HFD-fed mice compared to their SD controls
at 5 months (Fig. 2b). It was previously reported that
HFD treatment can increase weight gain in APP-Tg
mice [35].
NAFLD begins with accumulation of fat vesicles in the
liver cells (steatosis) which does not disturb normal functions of the liver. However, further damage including oxidative stress and mitochondrial abnormalities can induce
secondary inflammation and immune cell infiltration in
the liver which is known as steatohepatitis [12, 20]. To further characterize the liver pathology in HFD-fed mice, we
performed immunohistochemistry to examine immune cell
infiltration in the liver (hepatitis), as well as oil red-O staining to evaluate fat deposition in the liver cells (steatosis)
(Fig. 2c, d). We observed multifocal hepatitis and substantial steatosis in WT and APP-Tg mice fed with HFD,
whereas the livers of mice fed with SD were devoid of
hepatitis or steatosis (Fig. 2c). Although the livers of both
WT and APP-Tg mice fed with HFD showed marked lipid
droplet deposition, WT mice exhibited larger pockets of
fat deposits than APP-Tg mice (Fig. 2d, e). Analysis of
inflammatory leukocyte subpopulations revealed an
increase in CD4+, CD8+, B220+, and F4/80+ cells in the
livers of both WT and APP-Tg mice fed with HFD compared to their respective SD-fed controls (Fig. 2f). We next
determined whether NAFLD induced a systemic proinflammatory state in HFD mice. We performed gene
expression analysis of pro-inflammatory cytokines from
the livers of WT and App-Tg mice fed with SD or HFD
using quantitative PCR (qPCR). We observed increased expression of TNF-α, IL-6 and IL-17 in both WT and APPTg mice on HFD compared to SD controls (Fig. 2g). These
findings indicate that HFD-induced NAFLD caused an
acute inflammatory state, in the absence of increased
weight gain, which accelerated plaque formation in APPTg mice but not in WT mice.

HFD induced neuro-inflammation in both WT and APP-Tg
mice in acute stage AFLD

Peripheral inflammation, that is, inflammation induced
outside the CNS, has long been associated with inducing
CNS inflammation leading to neurodegeneration [12, 36].
To determine whether NAFLD-induced inflammation
(which initially starts in the liver) induces CNS inflammation in mice fed with HFD that may account for the
accelerated plaque burden in APP-Tg mice (Fig. 1), we
performed cytokine gene expression analysis on the brains
of WT and APP-Tg mice fed with either HFD or SD. We
observed higher levels of TNF-α and IL-6 mRNA in the
brains of APP-Tg mice on HFD compared to SD controls
(Fig. 3a). Interestingly, WT mice on HFD expressed higher
levels of IL-1β and IL-17 mRNA in the CNS compared to
SD controls (Fig. 3b). This indicates that peripheral
inflammation has a significant effect on induction of CNS
inflammation (Fig. 3b).
Toll-like receptors (TLRs), which are innate immune
receptors that recognize microbial components called
pathogen-associated molecular patterns (PAMPS) or endogenous ligands released by necrotic or injured cells
called damage-associated molecular patterns (DAMPS),
have been recently described in CNS inflammation [37].
TLR association with specific DAMPs leads to receptor
activation, which subsequently leads to initiation of an inflammatory cascade such as the one observed in Fig. 3a, b.
We investigated whether TLRs were altered in the CNS of
WT or APP-Tg mice fed with HFD compared to controls
during acute NAFLD. We focused on TLRs 1, 2, and 6 as
these TLRs are known to recognize lipoproteins and
glycolipids among others [38]. We observed significant
upregulation of TLR 1, 2, and 6 in the brains of WT and
APP-Tg mice fed with HFD compared to SD controls
(Fig. 3c). This confirms that HFD induced a potent inflammatory cascade inducing TLRs and culminating in secretion of pro-inflammatory mediators in the CNS.
Microgliosis is characterized by an increase in the number activated microglial cells accumulating around CNS lesions or during CNS injury and is believed to contribute to
CNS pathology in models of neuro-inflammation [39, 40].
We found that WT and APP-Tg mice fed with HFD

Kim et al. Journal of Neuroinflammation (2016) 13:1

Fig. 3 (See legend on next page.)

Page 8 of 18

Kim et al. Journal of Neuroinflammation (2016) 13:1

Page 9 of 18

(See figure on previous page.)
Fig. 3 Brains of HFD-fed mice have increased inflammation and microglial activation. mRNA expression of pro-inflammatory cytokine in brains of APP-Tg
(a) and WT mice (b). ** indicates p < 0.01 (two-tailed student t test, n = 2 performed in triplicates representative of four independent experiments). c Brain
mRNA expression of TLR1, TLR2, and TLR6 of WT or APP-Tg mice after being on SD or HFD for 2 months. *, **, *** indicate p < 0.05, p < 0.01, and p < 0.001
(two-tailed student t test, n = 2 performed in triplicates representative of four independent experiments). d Representative images of Iba-1 (red) near the
choroid plexus from WT mice and APP-Tg mice fed with SD or HFD for 2 or 5 months, or initially with HFD for 2 months and then put back on SD for
3 months. Nucleus was counter-stained with DAPI (blue). e Intensity of Iba-1 expression from d measured from different fields (n = 20, three mice/group)
using Zen Software (Carl Zeiss). ** and *** indicate where p < 0.01 and p < 0.001, respectively. (two-way ANOVA with Bonferroni post-test) f Representative
image of relative localization of Iba-1 (red) with β- amyloid plaque (green) from cortices of brains of mice fed with SD or HFD for 2 months. Nucleus was
counter-stained with DAPI (blue). Scale bar = 50 μm. g Intensity of Iba-1 signal from (f) was measured from different plaques using Zen Software (Carl Zeiss)
(n = 20, five mice/group). *** indicates p < 0.001 (two-tailed student’s t test)

showed markedly pronounced staining for the activated
microglial marker Iba-1, in areas surrounding the choroid
plexus (Fig. 3d and Additional file 2: Figure S2). Interestingly, despite the absence of plaques in WT mice on HFD,
these mice showed intense Iba-1 staining and increased
microglial cell numbers, suggesting that the CNS of these
mice is being primed for a neuroinflammatory or pathological event (Fig. 3d, e). Interestingly, Iba-1 staining was
significantly reduced in mice that were removed from HFD
after 2 months, indicating that HFD-induced systemic inflammation is the major factor contributing to CNS inflammation and microglial activation (Fig. 3d, e). We also
observed Iba-1 staining in APP-Tg mice fed with SD, albeit
to a lesser extent (Fig. 3d, e), suggesting pre-existing proinflammatory conditions in the CNS of these mice as
previously reported [41]. Since microglial cell activation is
higher in the choroid plexus of HFD-fed mice, we asked
whether such increased microglial activation is observed in
plaque-rich areas in the brains of APP-Tg mice fed with
HFD. Indeed, we observed higher microglial activation in
plaque-rich regions in brains from mice fed HFD for
2 months compared to those that were fed SD (Fig. 3f, g).
Increased microglial activation was also observed in cortical
and hippocampal areas devoid of β-amyloid plaques in
HFD-fed WT and APP-Tg mice compared to their SD-fed
controls (Additional file 3: Figure S3 A–D). This indicates
that HFD-induced NAFLD can trigger generalized microglial activation in the brains of both WT and APP-Tg mice.
Impact of HFD on chronic disease: NAFLD caused advanced
signs of AD in both WT and APP-Tg mice 1 year later

To mimic the life-long diet pattern in humans, we kept
WT and APP-Tg mice on HFD for up to 1 year to evaluate
its impact on systemic as well as on brain inflammation
and subsequent AD pathogenesis. First, we analyzed the
accumulation of fat deposition (steatosis) in the liver after
1 year of HFD treatment in both WT and APP-Tg mice.
We observed significantly higher accumulation of fat in
both WT and APP-Tg mice fed with HFD, indicating ongoing NAFLD (Additional file 4: Figure S4). Because we
observed accelerated plaque formation in APP-Tg mice at
2 and 5 months on HFD that is comparable with the
plaque loads and sizes seen in these mice around 18–24

months on SD, we anticipated an even greater plaque burden in APP-Tg mice fed with HFD for 1 year. Surprisingly,
instead of increased plaques, we observed a significant
decrease in overall plaque load in APP-Tg mice on HFD
compared to those on SD (Fig. 4a). We examined and
quantified Aβ plaque deposition in the cortex and hippocampus (Fig. 4a). We observed a dramatic reduction in Aβ
plaques in HFD-fed mice compared to SD-fed controls in
these regions (Fig. 4a, c). Also, close-up images of plaques
from these mice showed increased reactive astrocyte infiltration in SD-fed mice compared to HFD-fed mice (Fig. 4b).
Moreover, from 2 months (Fig. 4d upper panel) and up to
1 year (Fig. 4d bottom panel) of HFD treatment, we observed a reduction of GFAP signal in the hippocampus
compared to control treatment (Fig. 4e). We hypothesized
that the reduced plaque load may be a result of neuronal
and/or glial cell death or due to increased plaque clearance
by astrocytes, which can exert a protective response to fibrillar Aβ by removing it from the CNS [42]. To determine
whether the decreased plaque load in the CNS of APP-Tg
mice was the result of neuronal death leading to a decrease
in Aβ production, we stained frozen brain sections with
antibodies to TUNEL which stains DNA in dead or dying
cells, and to NeuN which stains neurons. We observed
higher incidence of TUNEL-positive NeuN cells in HFDfed mice compared to SD-fed APP-Tg mice (Fig. 4f, g). Further, quantification of neuronal cells in the cortex showed
that they were significantly decreased in APP-Tg mice fed
with HFD compared to SD controls (Fig. 4h, i). Also, the
thickness of the cortex was shrunken in APP-Tg mice fed
with HFD compared to SD controls (Fig. 4h, j). Moreover,
the intensity of NeuN-positive signal in the dentate gyrus
was reduced in APP-Tg mice fed with HFD compared to
SD-fed controls (Fig. 4h, k). Since astrocytes and neurons
are major producers of Aβ, these findings suggest that reduction in neuronal cells and astrocytes may be responsible
for the reduced plaque burden.
Long-term HFD-induced AD plaques and neuronal cell
loss in WT mice

WT mice developed inflammation both in the periphery
and in the CNS similar to and to some degree greater
than APP-Tg mice in acute NAFLD (Figs. 2 and 3).
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Fig. 4 Long-term HFD decreased NeuN+ cells, Aβ plaques, and astrocytes in APP-Tg mice. a Representative images of cortex (left panel) or hippocampus
(right panel) from APP-Tg mice fed with SD or HFD for 1 year, stained with anti-6E10 anti-β-amyloid antibody (green), anti-GFAP (red), and DAPI (blue).
Scale bar = 200 μm. b Representative zoomed-in images of reactive astrocyte (red) around plaque (green) from the cortex of SD or HFD-fed APP-Tg mice.
Scale bar = 50 μm. c Number of plaques from different regions of cortex (n = 10) or hippocampus (n = 10). * indicates p < 0.05 (two-tailed student’s t test,
n = 2 mice/group, representative of two independent experiments). d Representative with SD or HFD for 2 months (top panel) or 1 year
(bottom panel) stained with anti-NeuN (red), and anti-GFAP antibody (gold). Zoomed-in image was inserted as inlet. e Relative intensity of
GFAP signal from d (n = 10). ** indicates p < 0.01 (two-tailed student’s t test, twice mice/group, representative of two independent experiments). Representative images (f) and quantitative analysis (g) of images from brain cortex of APP-Tg mice fed with SD or HFD stained with NeuN (red), or
TUNEL (green). TUNEL/NeuN double positive cells were counted from ten different fields and quantified as a percentage of total cell count. *** indicates p
< 0.001 (two-tailed student’s t test, two mice/group). h Representative image of brain sections from SD or HFD-fed APP-Tg mice stained with anti-NeuN
antibody (red). Dotted lines indicate the outline of NeuN-positive signal in cerebral cortex. i Quantitative analysis
of h *** indicates p < 0.001 (two-tailed student’s t test, two mice/group). j Cortical thickness of brains from SD or HFD-fed mice measured
from ten different fields. ** indicates p < 0.001 (two-tailed student’s t test, two mice/group). k Quantitative analysis of h, showing intensity
of NeuN-positive signal measured from ten different fields of dentate gyrus from mice fed SD or HFD. ** indicates p < 0.001 (two-tailed
student’s t test, two mice/group)
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Brains of WT mice had increased numbers of activated
microglial cells and high levels of pro-inflammatory mediators but no evidence of plaque induction during acute
NAFLD. We examined brains of WT mice to determine
whether aging (6 months later) induced Aβ plaques in the
presence of HFD. Indeed, we observed plaque formation in
the cerebral cortex of WT mice fed with HFD (Fig. 5a).
This finding is significant because it indicates that HFDinduced chronic inflammation plus aging is sufficient to induce signs of AD in mice lacking genetic predisposition to
AD (Fig. 5a). To test whether WT mice also show increased neuronal apoptosis as was observed in APP-Tg
mice, we performed TUNEL/NeuN double-staining. Similar to APP-Tg mice, we observed a higher incidence of
TUNEL-positive NeuN staining (not significant) in WT
mice on HFD compared to SD (Fig. 5b, c). To test if
HFD induced neuronal loss, we quantified the number
of NeuN-positive cells in different brain regions. Indeed, we observed a statistically significant reduction of
NeuN-positive signal in the cortex (Fig. 5d, e) and reduced cortical thickness (Fig. 5d, f ) in WT mice fed
with HFD compared to SD controls. Also, the intensity
of NeuN-positive signal in the dentate gyrus was reduced in WT mice fed with HFD compared to SD controls (Fig. 5d, g). This suggests that long-term HFD
treatment in WT mice is sufficient to induce plaque
formation and neuronal loss. Interestingly, we did not
observe any decrease or reduction in astrocytes or Aβ
plaque deposition in the brains of WT mice on SD vs.
HFD as was observed in APP-Tg mice (Additional file
5: Figure S5).
Long-term HFD induced advanced signs of AD in WT and
APP-Tg mice

In addition to Aβ senile plaque deposits, aggregation of
neurofibrillary tangles composed of hyperphosphorylatedTau (pTau) is a prominent hallmark of advanced AD. Tau
is the microtubule-associated protein (MAP) that is
involved in the delivery of neurotransmitter signals
through microtubule tracks in axons [43, 44]. In its hyperphosphorylated state such as in AD, or tauopathies, Tau is
aggregated and unable to relay proper neurotransmission,
leading to neuronal dysfunction [10, 11, 45]. To test
whether tauopathy is induced in APP-Tg mice 1 year after
being on HFD, we stained the brains of mice fed with
either HFD or SD with an antibody that binds to pTau.
We observed very intense pTau staining in the hippocampus and cortex of APP-Tg mice but not in SD controls,
indicating that long-term HFD induced major advanced
signs of neurodegeneration (Fig. 6a). We next determined
whether WT mice on HFD also exhibit pTau staining. Indeed, similar to APP-Tg mice, WT mice exhibited intense
pTau staining in the dentate gyrus that was not observed
in SD-fed mice (Fig. 6a). This was further confirmed by
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Western blot using pTau-specific antibodies (S396 and
AT8) showing increased ratio of pTau/Tau in both HFDfed WT and APP-Tg mice compared to their SD controls
(Fig. 6b, c). These findings strongly indicate that HFD induced major advanced signs of neurodegeneration, not
only in animals predisposed to AD (APP-Tg mice) but was
sufficient to induce them in WT mice as they age.
We next investigated whether cerebral amyloid angiopathy (CAA), a sign of advanced AD characterized by accumulation of Aβ1–40 in the brain vasculature and believed
to cause micro-infarction leading to neurological dysfunction and neuronal death, was induced by HFD [46, 47]. Aβ
deposition in cerebral vessels lowers the force of Aβ
clearance, resulting in increased parenchymal Aβ buildup. We examined brains of mice after double-staining
with antibodies to Aβ and CD31 (marker for the endothelial vasculature). We observed intense and frequent signs
of CAA, evidenced by Aβ accumulation in the vessels of
WT and APP-Tg mice fed with HFD but not in SD
controls (Fig. 6d, e). Throughout the brains of WT and
APP-Tg mice, we observed what appears to be a high frequency of broken or fragmented vessels (Fig. 6f). These
findings indicate that HFD can induce signs of advanced
AD in WT mice and profoundly accelerate signs of
advanced AD in APP-Tg mice fed with HFD.
HFD decreased LRP1 and increased the inflammatory
profile in the brains of WT and APP-Tg mice during
chronic NAFLD

LRP1 is highly expressed in, neurons and glial cells, as well
as in the liver and vascular smooth muscle, and functions
in the clearance and trafficking of Aβ from the CNS.
However, studies show that LRP1 is also involved in Aβ
production [31]. Thus, LRP1 involvement in Aβ synthesis
and clearance makes it a prime target in AD pathogenesis.
Deletion of LRP1 exacerbated Aβ deposition and
increased CAA (Kanekiyo et al., 2012). We investigated
whether LRP1 expression is altered in the CNS of HFDfed mice both at early (acute NAFLD, 2 months) and
chronic NAFLD (after 1 year on HFD) compared to SD
controls. We observed increased LRP1 expression in the
brains of APP-Tg mice fed with HFD but not in HFD WT
mice (Fig. 7a). However, in chronic NAFLD, both WT and
APP-Tg mice fed with HFD expressed significantly lower
levels of LRP1 in CNS tissue compared to SD controls
(Fig. 7a). This decrease in LRP1 expression is consistent
with the increased neurodegenerative changes observed in
chronic disease and may reflect a protective role for LRP1
in AD [31].
ApoE is a known risk factor for AD. Its variant ApoE4 increases the risk of AD and accelerates AD onset (Bu, 2009;
Liu et al., 2013). ApoE is a ligand for LRP1, and its main
function is the cellular transfer of lipids through LRP1 on
the cell surface. There is mixed evidence as to whether
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Fig. 5 Long-term HFD induced Aβ plaque formation in brains of WT mice. a Representative images of brain sections from HFD-fed WT mice stained
with anti-NeuN (red) and anti-6E10 (green). b Representative images of brain sections (cortex) from SD or HFD-fed WT mice double-stained with antiNeuN (red) and TUNEL (green). c TUNEL/NeuN double positive cells were counted from ten different fields and quantified as a percentage of total cell
count. d Representative image of brain sections from SD or HFD-fed WT mice stained with anti-NeuN antibody (dotted lines indicate the
outline of NeuN-positive signal in the cerebral cortex. e Quantitative analysis of d, showing numbers of NeuN+ cells from ten fields of the
brain. ** indicates p < 0.01 (two-tailed student’s t test, two mice/group). f Comparison of cortical thickness of brains from SD or HFD-fed mice. Thickness
of cortex was measured from ten different fields. ** indicates p < 0.01 (two-tailed student’s t test, two mice/group). g Quantitative analysis
of d, capturing the intensity of NeuN-positive signal measured from ten different fields of the dentate gyrus from brains of mice fed with SD or HFD.
** indicates p < 0.01 (two-tailed student’s t test, two mice/group). These are representative findings from two independent experiments

ApoE is involved in binding and/or clearance of Aβ [48]. It
is speculated that ApoE may inhibit or facilitate LRP1mediated endocytosis of Aβ [49]. We therefore analyzed
ApoE expression in both acute and chronic NAFLD and

found no difference in ApoE expression in acute or chronic
NAFLD in WT or APP-Tg mice (Fig. 7b). This indicates
that ApoE expression/function remains relatively unchanged despite accelerated signs of neurodegeneration
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Fig. 6 Long-term HFD induced advanced signs of AD in WT and APP-Tg mice. a Representative images of hippocampus from WT and APP-Tg mice fed
with SD or HFD for 1 year, stained with anti-phosphorylated-Tau (S396) antibody. b, c Western blot analysis of brain homogenate of WT or APP-Tg mice
fed with SD or HFD for 1 year (b). Phosphorylated-Tau was detected with S396 or AT8 antibody and total Tau protein was detected with anti-Tau antibody.
GAPDH was used as loading control. Intensity of phospho-Tau was normalized by that of Tau protein which was further normalized by intensity of GAPDH
and depicted in graph (c). ** indicates p < 0.01. (two-tailed student’s t test, n = 2). d Representative brain sections from WT mice fed SD or HFD and stained
with anti-CD31 (red) and anti-β- amyloid antibody, 6E10 (green) to assess the degree of cerebral amyloid angiopathy (CAA) and vasculopathy. The top
three panels depict SD controls, the bottom three panels show HFD-induced CAA. e Representative brain images from APP-Tg mice double-stained
with antibodies to β-amyloid (6E10) and CD31 (vasculature) for SD (top three panels) or HFD (bottom three panels) to evaluate CAA. f Quantification
of fragmented vessels taken over multiple microscopic fields throughout the brains of WT and APP-Tg mice fed with SD or HFD. *** indicates p <
0.001 (Two-tailed student’s t test, ten fields/mouse, n = 2 mice/group)

and neuronal loss. In contrast, LRP1 expression increased
in acute/early phase of NAFLD in APP-Tg mice, but was
unchanged in WT mice on HFD. LRP1 levels decreased
significantly during chronic NAFLD in both WT and APPTg mice on HFD. This leaves us to speculate that a

decrease in LRP1 expression/function is linked to advanced
signs of AD.
To determine whether systemic inflammation was
maintained through the chronic phase of NAFLD, we
examined the cytokine profiles of lymphocytes in
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Fig. 7 Long-term HFD decreased LRP1 and maintained chronic inflammation in brains of WT and APP-Tg mice mRNA expression of LRP1 (a) or ApoE (b)
was analyzed in the brains of mice fed SD or HFD for 2 months or 1 year by quantitative real-time PCR. * and ** indicate p < 0.05 and p < 0.01, respectively
(two-tailed student’s t test, n = 2 mice/group performed in triplicates, representative of two independent experiments). c Splenocytes from mice fed SD
or HFD for 1 year were stimulated with PMA-ionomycin for 3 days, supernatants were collected and pro-inflammatory cytokines (TNF-α, IL-6, IL-17) were
quantified by ELISA. *, **, and *** indicate p < 0.05, p < 0.01, and p < 0.001, respectively (two-tailed student’s t test, n = 2 mice/group performed in triplicates,
representative of two independent experiments). d mRNA expression level of pro-inflammatory cytokines (TNF-α, IL-6, IL17) was analyzed in brain samples
from mice fed HFD or SD for 1 year by quantitative real-time PCR * and ** indicate p < 0.05 and p < 0.01, respectively (two-tailed student’s t test, n = 2
mice/group performed in triplicates, representative of two independent experiments)

peripheral lymphoid organs of APP-Tg mice after
1 year on SD or HFD. We observed increased TNF-α,
IL-6, and IL-17 in APP-Tg mice fed with HFD compared to SD controls (Fig. 7c). Similarly, lymphocytes
from WT mice fed with HFD secreted high levels of
the pro-inflammatory cytokines TNF-α, IL-6, and IL17 compared to their SD counterparts (Fig. 7c). To
determine whether this chronic HFD-induced systemic
inflammatory profile is consistent with the inflammatory
profile of the CNS, we performed quantitative RT-PCR of
these cytokines on brain samples. Indeed, we observed
that these cytokines were highly upregulated in the brains
of WT and APP-Tg mice fed with HFD compared to their
SD counterparts (Fig. 7d). Together, these results suggest
that augmented systemic immune responses induced by
HFD have a sustained impact on increased brain inflammatory response and profoundly impact neurodegeneration (Fig. 7d).

Discussion
We demonstrate that a modest increase in dietary lipids
fed to WT or APP-Tg mice induced acute inflammation
of the liver followed by a chronic inflammatory state.
This HFD-induced acute inflammation was characterized by invasion of inflammatory immune cells into the
liver parenchyma and increased production of proinflammatory cytokines by immune cells locally (liver)
and systemically (lymphoid organs). Concomitant with
this increased peripheral inflammatory state, we observed profound acceleration in neurodegenerative signs
and increased neuro-inflammation in APP-Tg mice
compared to mice that remained on SD. We observed
acceleration in β-amyloid plaque formation leading to
higher plaque loads, larger plaque size, and increased
microgliosis, and astroglyosis in APP-Tg mice. In AD
patients’ brain, activated microglial cells have been
observed around plaques and were initially thought to
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be a clearance mechanism to remove Aβ plaques from
the CNS. However, these activated microglial cells did
not reduce plaque burden [41], but induced neuronal
damage instead. In our study, APP-Tg mice on SD exhibited activated microglial cell accumulation in the
brain which is consistent with a previous report of a
pro-inflammatory state in these mice [42]. Compared to
SD-fed mice, microglial cell accumulation was increased
by about fourfold in HFD-fed mice, and this correlated
with increased pro-inflammatory cytokine expression in
these mice. This increase in both CNS and peripheral inflammation was reversed when mice were removed from
HFD and put back on SD; we observed decreased activated microglial cell numbers, decreased liver pathology,
and decreased pro-inflammatory cytokines in the CNS.
This reversal in inflammation was consistent with reduced Aβ plaque burden. This indicates that induction
of NAFLD in the liver may be an important factor that
can induce the accelerated signs of AD observed in
APP-Tg mice.
Interestingly, WT mice on HFD exhibited a similar increase in activated microglia accumulation even though
they did not exhibit signs of Aβ plaque deposition at 2 or
5 months on HFD. WT mice on HFD exhibited more pronounced lipid deposits in liver cells than APP-Tg mice, but
they did not develop Aβ plaques in the acute phase of
NAFLD. WT mice fed with HFD showed increased proinflammatory cytokine gene expression (TNF-α, Il-6 and
IL-17) in the liver and in peripheral lymphoid organs, and
liver pathology was more pronounced in WT mice, with
higher immune cell infiltration in the liver parenchyma.
Both IL-6 and Il-17 pro-inflammatory cytokines were
highly pronounced in WT mice but were almost absent in
SD controls. Il-6 and Il-17 play pathogenic roles in multiple
sclerosis [50, 51]. The profound increase in the expression
of these cytokine genes strictly coincides with increased
activated microglia in the CNS, potentially setting the stage
for the neurodegeneration we observed in WT mice on
HFD 1 year later. Moreover, when WT mice were removed
from HFD diet and placed on SD, inflammation ceased,
liver pathology was reverted, and activated microglial cells
were absent. Of interest was the absence of plaques in these
WT mice even though they showed all other signs of inflammation observed in the APP-Tg animals. This indicates
that HFD-induced systemic inflammation primed the CNS
for the neurodegeneration which we later observed. These
studies suggest that AD can be induced and driven by
acute-chronic systemic inflammation in individuals that are
not otherwise genetically predisposed. It also indicates that
early intervention can reverse the process.
The brains of APP-Tg mice on long-term HFD had
significantly less plaques compared to SD-fed mice.
APP-Tg mice showed a dramatic decrease in Aβ plaques in the hippocampus, the olfactory bulb, and the
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mid brain. Also striking was the absence of astrocytic
tracks in brain areas where Aβ plaques were absent or
diminished, such as the hippocampus and midbrain.
Moreover, we observed neuronal loss and increased
apoptotic neurons in hippocampus and mid brain. This
was not the case for older mice (15–24 months) on SD,
indicating that aging alone is not responsible for the
loss of astrocytes. As discussed above, removal from
HFD reduced plaque load and decreased inflammatory
signals. Thus, astrocytic loss may be a result of accelerated AD pathology resulting in CNS toxicity. Astrocyte
death can lead to neuronal death because of the critical
role they play in neuronal function [42]. Increased
neuronal death may also explain the decreased plaque
load in chronic AD due to decreased APP production.
Based on these studies, we conclude that chronic
inflammation induced outside the CNS (in the liver) is
sufficient to induce AD-like symptoms in the absence
of predisposing genetic factors.
Signs of CAA and hyperphosphorylated-Tau (pTau)
expression are representative of advanced AD. pTau aggregates and is unable to signal proper neurotransmission, leading to neuronal dysfunction; and CAA results
in a lack of Aβ clearance from the CNS. We observed
strong expression of pTau and evidence of CAA in both
WT and APP-Tg mice on HFD but not in SD controls.
pTau was increased in HFD-fed WT and APP-Tg mice
compared to SD controls, even though Aβ was induced
much later in WT mice. Thus, if CAA and tauopathy
represents advanced AD, one may argue that AD accelerated more dramatically in WT mice than APP-Tg
mice, and it may be regulated differently in genetically
predisposed (APP-Tg) vs. non-predisposed individuals
(WT). CAA involves deposition of amyloid in cerebral
vasculature and is a hallmark of advanced AD resulting
in pathological changes in cerebral blood vessels referred
to as vasculopathies. Signs of CAA were more extensive
in APP-Tg mice compared to WT mice on HFD. These
findings clearly indicate that HFD-induced inflammation
can result in significant CNS destruction and pathology
over a lifetime.
Low-density lipoprotein receptor-1 (LRP1) is involved
in a number of pathways linked to AD pathogenesis and
has multiple functions. It is most highly expressed in
brain, liver, and lungs. In the brain, it is highly expressed
in glial cells, neurons, and cells of the cerebral vasculature. LRP1 can directly regulate gene expression through
its intracellular domain and can regulate the endocytosis
of many diverse ligands including ApoE, APP, and Aβ.
LRP1 appears to have bimodal opposing functions linked
to AD pathogenesis. It is involved in Aβ clearance and
Aβ production. It mediates Aβ clearance by cellular uptake followed by lysosomal degradation and/or transcytosis of intact Aβ across the BBB to the circulation and
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consequent peripheral clearance [49]. We observed increased LRP1 expression in APP-Tg mice on HFD, but not
in WT mice, during the acute phase of NAFLD. Increased
LRP1 expression may represent its increased function in
clearance of Aβ from the CNS in APP-Tg mice during accelerated Aβ production. It is possible that LRP1 did not
increase in WT mice on HFD due to the absence of Aβ in
the CNS of these mice during acute NAFLD. However,
during chronic NAFLD, we observed a significant decrease
in LRP1 in the CNS of both WT and APP-Tg mice on
HFD. This decrease coincides with advanced signs of AD,
including reduced Aβ plaque load, reduced number of
neurons and astrocytes, and increased vascular destruction,
suggesting that LRP1 plays a protective role in AD. It is
possible that the reduction in LRP1 expression during
chronic NAFLD may be a result of glial and neuronal cell
loss, as these cells abundantly express LRP1. Alternatively,
advanced AD may have rendered LRP1 defective in clearing Aβ from the CNS.
It is interesting that no change in ApoE expression
was observed during acute or chronic stages of NAFLD,
despite significant neuronal and glial cell loss. The major
function of ApoE is to transport cholesterol and other
lipids in plasma and brain through a variety of cell surface receptors including LRP1 [49]. Astrocytes are the
main source of ApoE [25, 52]. Since cholesterol is a critical component of glial and neuronal cell membrane including the myelin sheath, it is possible that a reduction
of GFAP+ astrocytes resulted in limited cholesterol production needed for membrane synthesis and CNS repair.
However, this is unlikely since such a reduction may
have resulted in decreased ApoE. Other likely scenarios
for no change in ApoE include its function in cholesterol
trafficking was unhindered, whereas its function in Aβ
trafficking was defective, or that the reduced plaque burden in chronic NAFLD was the result of increased Aβ
trafficking by ApoE. The involvement of Aβ, LRP1, and
ApoE in neurodegeneration and AD pathogenesis is
quite complex and needs further investigation beyond
these studies.
Our studies address a growing problem in our society
that relates to metabolic syndromes due to diets high in
fat/lipid consumption and their impact on neurodegeneration. NAFLD is prevalent in as much as a third of the
world’s population. Similarly, AD frequency is rapidly
growing. We showed that a modest increase in dietary lipid
content caused increased systemic inflammation followed
by increased neuro-inflammation and accelerated AD signs
in APP-Tg mice. More importantly, we showed that WT
mice become susceptible to developing Aβ plaques after
long-term HFD intake and developed advanced cellular
signs of AD. Moreover, APP-Tg mice on HFD exhibit severe CNS damage stemming from the effects of chronic
HFD. These findings highlight a growing problem in our
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society whereby consumption of foods high in lipids over a
lifetime can have detrimental consequences such as accelerating signs of AD in potentially susceptible individuals or
inducing them in those that are not susceptible. An important and critical finding of these studies is that change
from HFD to SD, before irreversible CNS damage sets in,
completely reverses signs of AD. This suggests that life
style changes such as reducing one’s lipid/fat intake can
have a profound impact on disease outcome. Recent studies from others showed that a high-cholesterol diet (5 %)
fed to mice can induce advanced pathological signs of AD
[53–55]. Similar to our findings, these studies showed that
diets high in cholesterol increased hyperphosphorylatedTau deposition, and decreased cognitive function in both
WT and AD models [53–55]. Also, one of the studies
showed increased ventricular volume which is reminiscent
of the decreased cortical thickness and increased neuronal
apoptosis we observed in HFD-fed WT and APP-Tg mice
[55]. These findings are in line with ours and highlight a
critical role for a diet high in fats and lipids in inducing
pathological outcomes. However, our model differs in the
cholesterol content. We fed mice a diet containing 1 %
cholesterol plus 18 % triglyceride which consistently
induces NAFLD that is characterized by acute inflammation and significant liver damage in mice.

Conclusions
In summary, chronic high-fat diet induced NAFLD, and its
secondary neuro-inflammation is sufficient to cause neurodegeneration in both WT and APP-tg mice. We believe this
study stands to benefit millions of people who are in danger
of developing AD or people currently suffering from early
signs of AD or dementia. Future studies hinge on elucidating the fine changes conferred upon neuronal function
resulting in their loss or dysfunction, correlating with
behavioral and cognitive defects, and defining cerebral
vasculopathies resulting from these events.
Additional files
Additional file 1: Table S1. Sequences of primers used for quantitative
PCR analysis.
Additional file 2: Figure S1. Brain sections from SD and HFD-fed
WT mice at 2 months stained with Thioflavin S (Green). Sections were
counter-stained with DAPI to visualize nuclei. Scale bar = 200 μm.
Additional file 3: Figure S2. Zoomed-in images of Iba-1 (red) staining
of respective time points from Figure 2d. Nucleus was counter-stained
with DAPI (blue).
Additional file 4: Figure S3. Iba-1 (red) staining of cortical (A) and
hippocampal (C) areas of brains devoid of plaques from WT and APP-Tg
mice fed with SD or HFD for 2 months. Iba-1+cells were counted from
different fields of the cortex (n = 20 from two animals) and hippocampus
(n = 10 from two animals). ** and *** indicate p < 0.01 and p < 0.001,
respectively. (two-way ANOVA with Bonferroni post-test).
Additional file 5: Figure S4. Positive pixel count of oil O-red staining
in the liver of WT and APP-Tg mice fed with SD or HFD for 1 year. Fixed
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liver sections were stained with oil O-red and positive pixels (red) were
counted using Zen Software. **indicates p < 0.01. (two-way ANOVA with
Bonferroni post-test, n = 2).
Additional file 6: Figure S5. Representative images of hippocampal
sections from WT mice fed with SD or HFD for 1 year and stained with
anti-NeuN (pink), GFAP (gold). Scale bar = 200 μm.
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